EcoDrugPlus

Substance-P Receptor

Ensembl ID : ENSOKIG00005047200
Gene Symbol: LOC109880101
3 Cross references
188 Possible Orthologues:

Substance-P Receptor-Like

Ensembl ID : ENSOKIG00005034970
Gene Symbol: LOC109868626
3 Cross references
187 Possible Orthologues:

Synaptic Vesicular Amine Transporter

Ensembl ID : ENSOKIG00005011345
Gene Symbol: LOC109888781
3 Cross references
220 Possible Orthologues:

Synuclein Alpha

Ensembl ID : ENSOKIG00005034032
Gene Symbol: SNCA
1 Cross references
183 Possible Orthologues:

Tachykinin Receptor 1

Ensembl ID : ENSOKIG00005003358
Gene Symbol: TACR1
3 Cross references
190 Possible Orthologues:

Tachykinin Receptor 1

Ensembl ID : ENSOKIG00005004460
Gene Symbol: TACR1
3 Cross references
190 Possible Orthologues:

Tachykinin Receptor 2

Ensembl ID : ENSOKIG00005050897
Gene Symbol: TACR2
1 Cross references
190 Possible Orthologues:

Tachykinin Receptor 3

Ensembl ID : ENSOKIG00005019778
Gene Symbol: TACR3
3 Cross references
242 Possible Orthologues:

Telomerase Reverse Transcriptase

Ensembl ID : ENSOKIG00005005032
Gene Symbol: TERT
3 Cross references
189 Possible Orthologues:

Thromboxane A Synthase 1 (Platelet)

Ensembl ID : ENSOKIG00005034310
Gene Symbol: TBXAS1
1 Cross references
213 Possible Orthologues:

Thromboxane A2 Receptor

Ensembl ID : ENSOKIG00005000339
Gene Symbol: LOC109881250
3 Cross references
186 Possible Orthologues:

Thromboxane A2 Receptor-Like

Ensembl ID : ENSOKIG00005016155
Gene Symbol: LOC109902266
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).